Bladder Cancer

In North America, bladder cancer is the fourth most common cancer in men and in the top ten for women. In the United States, approximately 70,000 patients are newly diagnosed with bladder cancer each year.

What is Bladder Cancer?

Bladder cancer refers to the growth of a tumor within the lining of the bladder. In some cases, the tumor can invade surrounding tissue and spread to other parts of the body.

What Causes Bladder Cancer?

Bladder Cancer Diagnosis

Bladder Cancer Treatment

Bladder Cancer Types

Symptoms of Bladder Cancer

What is Intravesical Therapy?

Bladder Cancer Biomarkers

Bladder Cancer Histopathology

Endoscopic Imaging for Bladder Cancer

Thromboembolism in Bladder Cancer

Non-Invasive Diagnostic Strategies for Bladder Cancer

See more featured articles »

Bladder Cancer Genomics

Bladder Cancer Risk Factors

Muscle Invasive Bladder Cancer (MIBC)

Muscle Invasive Bladder Cancer (MIBC) Diagnosis and Treatment

Latest Bladder Cancer News and Research

Bladder cancer is more aggressive and advanced in South Texas, study shows

Bladder cancer is more aggressive and more advanced in South Texas residents than in many parts of the country, a study by the Mays Cancer Center, home to UT Health San Antonio MD Anderson, indicates.

25 Feb 2021

COVID-19 and lung cancer have a common pathway, say researchers

A new preprint on the bioRxiv* server describes the common features COVID-19 shares with lung cancer.

19 Feb 2021

Using complementary disinfection strategies to make swimming pools safer

Swimming in indoor or outdoor pools is a healthy form of exercise and recreation for many people. However, studies have linked compounds that arise from chlorine disinfection of the pools to respiratory problems, including asthma, in avid swimmers.

17 Feb 2021

Study: Targeted therapy prolongs survival in patients with advanced bladder cancer

In a new study led by researchers at Yale Cancer Center, the drug enfortumab vedotin (EV) significantly prolonged survival as compared with standard chemotherapy in patients with locally advanced or metastatic urothelial carcinoma or bladder cancer, who had previously received platinum-based treatment and a PD-1–PD-L1 inhibitor.

15 Feb 2021

Liquid biopsy can help gauge the effectiveness of therapy for colorectal cancer

A new study from Washington University School of Medicine in St. Louis demonstrates that a liquid biopsy examining blood or urine can help gauge the effectiveness of therapy for colorectal cancer that has just begun to spread beyond the original tumor.

14 Feb 2021

New type of drug significantly increases survival of bladder cancer patients

A new type of drug that helps target chemotherapy directly to cancer cells has been found to significantly increase survival of patients with the most common form of bladder cancer, according to results from a phase III clinical trial led in the UK by Queen Mary University of London and Barts Health NHS Trust.

13 Feb 2021

Dramatic changes seen in delivery of radiotherapy treatments during coronavirus pandemic

Dramatic changes were seen in the delivery of radiotherapy treatments for cancer during the first wave of the coronavirus pandemic in England.

22 Jan 2021

New study can help determine effectiveness of chemotherapy in patients with bladder cancer

In patients with bladder cancer, chemotherapy effectiveness is partially determined by the body's immune system response to the malignancy. This is the conclusion of research conducted by a team of scientists from Charité - Universitätsmedizin Berlin and the Berlin Institute of Health.

15 Jan 2021

Study demonstrates safety of novel immuno-oncology therapy in patients with advanced solid tumors

A novel therapy designed to help stimulate the body's immune system response against cancer appears to be safe to use as alone or in combination with immune checkpoint inhibitors.

1 Dec 2020

Machine learning increases the accuracy of anti-cancer drug response predictions

With the advent of pharmacogenomics, machine learning research is well underway to predict the patients' drug response that varies by individual from the algorithms derived from previously collected data on drug responses.

2 Nov 2020

Phase II NRG Oncology trial evaluates two regimens for muscle-invasive bladder cancer

Bladder preservation with trimodality therapy can be a safe and effective alternative to cystectomy for selected patients with muscle-invasive bladder cancer.

27 Oct 2020

Scientists uncover a novel cellular mechanism for disposing of misfolded proteins

About 30 years ago, Dr. Richard Sifers set out on a journey to discover why people with a rare condition known as alpha1-antitrypsin deficiency present with high variation in the severity of liver disease.

21 Oct 2020

Neoadjuvant trial of combination immunotherapy has favorable outcomes in bladder cancer patients

Neoadjuvant, or pre-surgical, combination treatment with the immune checkpoint inhibitors tremelimumab (anti-CTLA-4) and durvalumab (anti-PD-1) was well-tolerated and showed early signs of activity in certain patients with localized bladder cancer who do not have standard treatment options available, according to a Phase I clinical trial conducted by The University of Texas MD Anderson Cancer Center.

13 Oct 2020

UroCAD assay is better than urine cytology in detecting bladder cancer

Analysis of DNA copy number variants (CNVs) in the cells exfoliated in urine showed better sensitivity and similar specificity in detecting urothelial carcinoma compared with urine cytology.

9 Oct 2020

Robotic surgery poses challenges as hospital resume elective surgery amid COVID-19

Robotic surgery plays a major role in modern management of prostate cancer, bladder cancer, and other conditions treated by urologists. But it also poses some special challenges as hospitals resume elective surgery amid the COVID-19 pandemic.

7 Oct 2020

Antibody improves progression-free survival in patients with advanced prostate cancer

An antibody for treating advanced prostate cancer improves progression-free survival in patients with metastasised, castration-resistant prostate cancer.

29 Sep 2020

PPI use linked to worse outcomes in urothelial cancer patients treated with atezolizumab

Proton pump inhibitor (PPI) use was associated with worse outcomes in patients with urothelial cancer treated with the immunotherapeutic atezolizumab (Tecentriq), compared with patients who did not use PPIs.

17 Sep 2020

Tobacco smoking linked to worse outcomes for bladder cancer patients after surgery

Patients treated for bladder cancer with a surgery known as radical cystectomy have worse outcomes if they are smokers, according to a systematic review and meta-analysis by Keck Medicine of USC.

15 Sep 2020

Study: Cigarette smoking is linked to worse outcomes in patients treated for bladder cancer

Patients treated for bladder cancer with a surgery known as radical cystectomy have worse outcomes if they are smokers, according to a systematic review and meta-analysis by Keck Medicine of USC. The study appeared in The Journal of Urology.

14 Sep 2020

Six genomics research projects receive grants to address the role of ethnicity in major cancers

Leading cancer scientists working with the New York Genome Center (NYGC) announced today that grants are being awarded to fund six projects that address the role of ethnicity in several major cancer types, taking advantage of the diversity of patients being treated at health care institutions throughout the New York City area.

8 Sep 2020